In 2019, Low and colleagues applied the CRISPR-Cas9 gene editing tool in hPSCs from ARPKD patients to correct a specific mutation in PKHD1 gene [130]. This evidence concerns the gene PKHD1 and autosomal recessive polycystic kidney disease.